Chinese state-owned firm signs deal with Pfizer to supply Covid-19 pill


68c40803-064b-47ef-9e73-9d07e6f183d9_98dc2753

Pfizer’s Covid-19 pill is one step closer to clinical use in China, with state-owned China Meheco Corp securing a deal with Pfizer to commercialise the drug within the year.

The Chinese company had signed a contract with Pfizer and was authorised to supply Paxlovid in China during the 2022 agreement period, China Meheco said in a statement on Wednesday night.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
SCMO , China , Covid-19 , Pills , Pfizer

Next In Aseanplus News

'Found happiness again' - Car tycoon Wolfgang Porsche, 82, marries for the fourth time
Family of businessman who died in police lockup awarded RM1.1mil
‘Not enough pay’ keeps recruits away at South Korean military
Property firm ISS insists it has ‘admin role’, but Hong Kong watchdog disagrees
Over 300 humanitarian workers killed in 2025, marking second deadliest year, says OCHA
Amnesty says India's review of location-tracking plan 'deeply concerning'
Factory of factories: China’s manufacturers join wave of overseas expansions
Wrecked James Bond car bought for RM5k now worth RM5.5mil after 3-year restoration
Thailand launches air strikes on Cambodia as border tensions reignite; two people reported death
FBM KLCI retreats on Fed jitters as investors stay on sidelines

Others Also Read